Probability of finding T1a and T1b (Incidental) prostate cancer during TURP has decreased in the PSA era

Prostate Cancer and Prostatic Diseases

Volumn 12, Issue 1, 2009, Pages 57-60

  Jones, J S ^a   Follis, H W ^a   Johnson, J R ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CANCER STAGING; CONTROLLED STUDY; EARLY DIAGNOSIS; HISTOPATHOLOGY; HUMAN; INCIDENTAL FINDING; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROBABILITY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; RISK ASSESSMENT; TIME; TRANSURETHRAL RESECTION;

HUMANS; INCIDENTAL FINDINGS; MALE; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TRANSURETHRAL RESECTION OF PROSTATE;

EID: 60349112692     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2008.14     Document Type: Article

References (18)

1. Murphy GP, Natarajan N, Pontes JE, Schmitz RL, Smart CR, Schmidt JD et al. The national survey of prostate cancer in the United States by the American College of Surgeons. J Urol 1982; 127: 928-934.
2. Endrizzi J, Optenberg S, Byers R, Thompson IM. Disappearance of well-differentiated carcinoma of the prostate: Effect of transurethral resection of the prostate, prostate-specific antigen, and prostate biopsy. Urology 2001; 57: 733-736.
3. Ornstein DK, Rao GS, Smith DS, Andriole GL. The impact of systematic prostate biopsy on prostate cancer incidence in men with symptomatic benign prostatic hyperplasia undergoing transurethral resection of the prostate. J Urol 1997; 157: 880-883.
4. Argyropoulos A, Doumas K, Farmakis A, Aristas O, Kontogeorgos G, Lykourinas M. Characteristics of patients with stage T1b incidental prostate cancer. Scand J Urol Nephrol 2005; 39: 289-293.
5. Moore GH, Lawshe B, Murphy J. Diagnosis of adenocarcinoma in transurethral resectates of the prostate gland. Am J Surg Pathol 1986; 10: 165-169.
6. Harkaway RC, Issa MM. Medical and minimally invasive therapies for the treatment of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2006; 9: 204-214.
7. Merrill RM, Feuer EJ, Warren JL, Schussler N, Stephenson RA. Role of transurethral resection of the prostate in population-based prostate cancer incidence rates. Am J Epidemiol 1999; 150: 848-860.
8. Fowler Jr JE, Pandey P, Bigler SA, Yee DT, Kolski JM. Trends in diagnosis of stage T1a-b prostate cancer. J Urol 1997; 158: 1849-1852.
9. Meguro N, Maeda O, Saiki S, Kinouchi T, Kuroda M, Usami M et al. Clinical significance of prostate specific antigen (PSA) and PSA density in the detection of T1a and T1b prostate cancer. Hinyokika Kiyo 1998; 44: 639-643.
10. Herranz Amo F, Verdu Tartajo F, Diez Cordero JM, Bueno Chomon G, Leal Hernandez F, Bielsa Carrillo A et al. Incidence of prostatic cancer in symptomatic patients with non-suspicious rectal palpation and PSA levels greater than 10 ng/ml. Actas Urol Esp 1999; 23: 316-322.
11. Horninger W, Reissigl A, Rogatsch H, Volgger H, Studen M, Klocker H et al. Prostate cancer screening in Tyrol, Austria: Experience and results. Eur Urol 1999; 35: 523-538.
12. Monda JM, Barry MJ, Oesterling JE. Prostate specific antigen cannot distinguish stage T1a (A1) prostate cancer from benign prostatic hyperplasia. J Urol 1994; 151: 1291-1295.
13. Ornstein DK, Rao GS, Smith DS, Andriole GL. The impact of systematic prostate biopsy on prostate cancer incidence in men with symptomatic benign prostatic hyperplasia undergoing transurethral resection of the prostate. J Urol 1997; 157: 880-883.
14. Zigeuner RE, Lipsky K, Riedler I, Auprich M, Schips L, Salfellner M et al. Did the rate of incidental prostate cancer change in the era of PSA testing? A retrospective study of 1127 patients. Urology 2003; 62: 451-455.
15. Sakr WA, Grignon DJ, Haas GP, Heilbrun LK, Pontes JE, Crissman JD. Age and racial distribution of prostatic intraepithelial neoplasia. European Urology 1996; 30: 138-144.
16. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-224.
17. Walz J, Graefen M, Chun FK, Erbersdobler A, Haese A, Steuber T. et al High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. Eur Urol 2006; 50: 498-505.
18. Jones JS. Saturation biopsy for detecting and characterizing prostate cancer. BJU Int 2007; 99: 1340-1344.